Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 29.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 29.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 04.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 18.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 24.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Report on Form 8-K and is incorporated into this Item 5.02 by reference. Mr. Szekeres’ decision to resign was amicable a |
| 23.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 12.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 20.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 03.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 22.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rent Report on Form 8-K is incorporated into this Item 5.02 by reference. 2 Pursuant to the Cooperation Agreement, e |
Stammdaten
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | HERON THERAPEUTICS, INC. /DE/ |
|---|---|
| Ticker | HRTX |
| CIK | 0000818033 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 187,2 Mio. USD |
| Beta | 1,42 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -20,195,000 | -0.12 | 255,877,000 | 14,333,000 | |
| 2025-09-30 | 10-Q | -17,495,000 | -0.10 | 248,950,000 | 14,885,000 | |
| 2025-06-30 | 10-Q | -2,381,000 | -0.02 | 232,090,000 | -27,258,000 | |
| 2025-03-31 | 10-Q | 2,635,000 | 0.01 | 235,752,000 | -28,453,000 | |
| 2024-12-31 | 10-K | -13,580,000 | -0.09 | 233,147,000 | -33,651,000 | |
| 2024-09-30 | 10-Q | -4,848,000 | -0.03 | 220,777,000 | -40,005,000 | |
| 2024-06-30 | 10-Q | -9,235,000 | -0.06 | 218,136,000 | -37,940,000 | |
| 2024-03-31 | 10-Q | -3,160,000 | -0.02 | 217,887,000 | -33,766,000 | |
| 2023-12-31 | 10-K | -110,559,000 | -0.80 | 222,506,000 | -33,973,000 | |
| 2023-09-30 | 10-Q | -25,008,000 | -0.17 | 229,199,000 | -27,786,000 | |
| 2023-06-30 | 10-Q | -42,059,000 | -0.35 | 201,224,000 | -39,284,000 | |
| 2023-03-31 | 10-Q | -32,768,000 | -0.27 | 220,878,000 | -11,429,000 | |
| 2022-12-31 | 10-K | -182,024,000 | -1.67 | 250,951,000 | 13,572,000 | |
| 2022-09-30 | 10-Q | -41,908,000 | -0.38 | 271,952,000 | 22,450,000 | |
| 2022-06-30 | 10-Q | -56,359,000 | -0.55 | 243,965,000 | -21,736,000 | |
| 2022-03-31 | 10-Q | -63,888,000 | -0.63 | 273,723,000 | 23,958,000 | |
| 2021-12-31 | 10-K | -220,683,000 | -2.24 | 305,706,000 | 77,570,000 | |
| 2021-09-30 | 10-Q | -52,408,000 | -0.51 | 352,388,000 | 118,843,000 | |
| 2021-06-30 | 10-Q | -61,015,000 | -0.62 | 404,250,000 | 160,112,000 | |
| 2021-03-31 | 10-Q | -52,614,000 | 310,932,000 | 196,225,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-08 | Rubric Capital Management LP | 10% Owner | Open Market Purchase | 2,387,225 | 1.50 | 3,580,837.50 | +114,9% | |
| 2025-08-08 | Morgan Adam | Director | Open Market Purchase | 1,766,546 | 1.50 | 2,649,819.00 | +85,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.